Base de dados : LILACS
Pesquisa : D12.776.124.486.485.114 [Categoria DeCS]
Referências encontradas : 997 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 100 ir para página                         

  1 / 997 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-978550
Autor: Martínez Téllez, Goitybell; Torres Rives, Bárbara; Gómez, Jorge Alexis; Prada Hernández, Dinorah M; Sánchez Rodríguez, Vicky.
Título: Eficacia diagnóstica de anticuerpos antipéptidos citrulinados de segunda y tercera generaciones para la artritis reumatoide / Diagnostic effectiveness of anti-citrullinated peptides antibodies of second and third generations for rheumatoid arthritis
Fonte: Rev. habanera cienc. méd;17(4):540-554, jul.-ago. 2018. tab, graf.
Idioma: es.
Resumo: Introducción: La artritis reumatoide es una enfermedad autoinmune caracterizada por la presencia de anticuerpos contra péptidos citrulinados, que constituyen indicadores para el diagnóstico de la enfermedad. Es necesario determinar la utilidad de diferentes métodos de determinación de estos anticuerpos para el diagnóstico de pacientes cubanos con artritis reumatoide. Objetivo: Determinar la eficacia de los ensayos de determinación de anticuerpos anti-CCP2 y anti-CCP3 para el diagnóstico de pacientes cubanos con artritis reumatoide. Material y método: Participaron 101 pacientes con artritis reumatoide, 58 pacientes con otras enfermedades reumáticas e inflamatorias y 43 individuos sanos. Se determinó la eficacia diagnóstica de los anticuerpos factor reumatoideo (FR), anti-CCP2 y anti-CCP3 medidos mediante ELISA, con el cálculo de la sensibilidad, especificidad, valores predictivos positivos y negativos. Resultados: El ensayo anti-CCP2 mostró un mejor balance sensibilidad (48,5 por ciento) y especificidad (98,0 por ciento). Cuando se fijó la especificidad a 98 por ciento, se observó la menor sensibilidad para el FR (40,3 por ciento). Utilizar los ensayos anti-CCP2 y FR aumentó la especificidad a 100 por ciento. Todos los autoanticuerpos mostraron asociación con la proteína C reactiva y correlación con la velocidad de sedimentación globular. Solamente los anticuerpos anti-CCP2 no mostraron correlación con el indicador clínico de actividad DAS 28. Conclusiones: Los anticuerpos anti-CCP2 son los de mayor eficacia para el diagnóstico de pacientes cubanos con artritis reumatoide. La determinación de FR permite identificar pacientes con artritis reumatoide seronegativos de anticuerpos anti-CCP2, por lo que la combinación de ambos inmunoensayos produce una mejoría en la eficacia diagnóstica(AU)

Introduction: Rheumatoid arthritis is an autoimmune disease characterized by the presence of antibodies against citrullinated peptides, which are one of the indicators for the diagnosis of a disease. The usefulness of different methods for the determination of these antibodies in the diagnosis of Cuban patients with rheumatoid arthritis is necessary to be established. Objective: To establish the diagnostic effectiveness of the second (anti-CCP2) and third (anti-CCP3) generation assays for the determination these antibodies against citrullinated peptides in Cuban patients with rheumatoid arthritis. Material and method: 101 patients with rheumatoid arthritis, 58 patients with other rheumatic and inflammatory diseases, and 43 healthy persons participated in the study. The diagnostic efficiency of rheumatoid factor (RF), anti-CCP2 and anti-CCP3 antibodies were determined using ELISA test, by calculating sensitivity, specificity, and positive and negative predictive values. Results: The anti-CCP2 assay showed a better balance of sensitivity (48.5 percent) and specificity (98.0 percent). The lower sensibility was observed for RF (40.3 percent) when the specificity was set at 98 percent. Specificity increased to 100 percent when anti-CCP2 and RF assays were used. All autoantibodies showed association with C-reactive protein and correlation with erythrocyte sedimentation rate. Only anti-CCP2 antibodies showed no correlation with the DAS28 clinical indicator. Conclusions: Anti-CCP2 antibodies are the ones of greater effectiveness in the diagnosis of Cuban patients with rheumatoid arthritis. RF identification allows to identify seronegative anti-CCP2 patients; therefore, the combination of both immunoassays leads to an improvement in the diagnostic effectiveness(AU)
Descritores: Artrite Reumatoide/diagnóstico
Técnicas e Procedimentos Diagnósticos/normas
Anticorpos Anti-Proteína Citrulinada/imunologia
-Estudos de Casos e Controles
Anticorpos Anti-Proteína Citrulinada/uso terapêutico
Anticorpos
Limites: Seres Humanos
Masculino
Feminino
Responsável: CU1.1 - Biblioteca Médica Nacional


  2 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1020049
Autor: Alves, Samara Pereira; Silva, Marilda Guimarães; Borges, Isabela Bruna Pires; Shinjo, Samuel Katsuyuki.
Título: Patients with pure dermatomyositis/polymyositis and anti-PM/Scl autoantibody resembling anti-synthetase syndrome / Pacientes com dermatomiosite/polimiosite pura e autoanticorpo anti-pm/scl sememlhante à síndrome anti-sintetase
Fonte: MedicalExpress (São Paulo, Online);5:mo18002, 2018. tab.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Resumo: OBJECTIVE: The anti-PM/Scl autoantibody has been described in patients with scleromyositis. However, there are scant studies evaluating its prevalence and reactivity in dermatomyositis and polymyositis. METHOD: A cross-sectional, single center study evaluating the anti-PM/Scl autoantibody in 85 dermatomyositis and 32 polymyositis patients, without overlapping syndrome, was conducted between 2000 and 2016. Clinical data and complementary examinations were reviewed from electronic medical records with pre-parameterized information. RESULTS: The mean age of dermatomyositis and polymyositis patients was 41.1 and 42.8 years, respectively. The presence of anti-PM/Scl was observed in 5 (5.9%) dermatomyositis and 2 (6.3%) polymyositis patients. Two of these patients also had the anti-Ku antibody. The relevant clinical manifestations of these 7 patients were constitutional symptoms (100% of cases), muscular (100%), pulmonary (85.7%) and joint (71.4%) involvement, "mechanic hands" (85.7%), Raynaud phenomenon (85.7%) and plantar hyperkeratosis (85.7%). The 7 patients had relapses of disease activity, but at conclusion of the present study, 5 had complete clinical response and 2 complete remission of the disease. CONCLUSION: There is a low frequency of the anti-PM/Scl autoantibody in dermatomyositis and polymyositis patients. In addition, patients with this autoantibody exhibit a similar pattern of manifestations to that of antisynthetase syndrome.

OBJETIVO: O autoanticorpo anti-PM/Scl foi descrito em pacientes com escleromiosite. No entanto, há escassos estudos avaliando sua prevalência e reatividade em dermatomiosite (DM) e polimiosite (PM). MÉTODOS: Estudo transversal, num único centro, que avaliou o autoanticorpo anti-PM/Scl em 85 DM e 32 PM, sem síndrome de sobreposição, no período entre 2000 e 2016. Os dados clínicos e os exames complementares foram revisados a partir de registros médicos eletrônicos com informações pré-parametrizadas. RESULTADOS: A média de idade dos pacientes com DM e PM foi, respectivamente, de 41,1 e 42,8 anos. A presença de anti-PM/Scl foi observada em 5 (5,9%) DM e 2 (6,3%) pacientes com PM. Dois desses pacientes também possuíam o anticorpo anti-Ku. As manifestações clínicas relevantes desses 7 pacientes foram sintomas constitucionais (100% dos casos), envolvimento muscular (100%), pulmonar (85,7%) e articular (71,4%), "mãos mecânicas" (85,7%), fenômeno de Raynaud (85,7 %) e hiperqueratose plantar (85,7%). Os 7 pacientes apresentaram recidivas da atividade da doença, mas, no final do presente estudo, 5 apresentaram resposta clínica completa e 2 remissões completas da doença. CONCLUSÃO: Há uma baixa freqüência do autoanticorpo anti-PM/Scl em pacientes com DM e PM. Além disso, os pacientes com este autoanticorpo apresentam um padrão semelhante de manifestações para a síndrome da antisintetase.
Descritores: Polimiosite
Dermatomiosite
Anticorpos
Miosite
Limites: Adulto
Responsável: BR501.1 - Biblioteca de Ciências da Saúde / Sede Botânico


  3 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Casanova, Cláudio
Texto completo
Id: biblio-841765
Autor: Aires, Juliana; Casanova, Claudio; Vernal, Sebastian; Nascimento, Margarida; Rodrigues, Sandra; Lerner, Ethan A; Roselino, Ana Maria.
Título: Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an endemic region of Brazil, and its immunogenicity in patients with American tegumentary leishmaniasis
Fonte: Mem. Inst. Oswaldo Cruz;112(2):116-122, Feb. 2017. tab, graf.
Idioma: en.
Resumo: BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.
Descritores: Leishmaniose Cutânea/imunologia
Leishmaniose Cutânea/sangue
Proteínas de Insetos/imunologia
Insetos Vetores/classificação
Anticorpos/imunologia
Anticorpos/sangue
-Psychodidae/química
Brasil
Ensaio de Imunoadsorção Enzimática
Immunoblotting
Estudos de Casos e Controles
Reação em Cadeia da Polimerase
Proteínas de Insetos/análise
Doenças Endêmicas
Limites: Animais
Masculino
Feminino
Coelhos
Responsável: BR1.1 - BIREME


  4 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-841749
Autor: Silva, Kleverton Ribeiro da; Mendonça, Vitor Rosa Ramos de; Silva, Kellen Matuzzy; Nascimento, Leopoldo Fabrício Marçal do; Mendes-Sousa, Antonio Ferreira; Pinho, Flaviane Alves de; Barral-Netto, Manoel; Barral, Aldina Maria Prado; Cruz, Maria do Socorro Pires e.
Título: Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil
Fonte: Mem. Inst. Oswaldo Cruz;112(1):53-63, Jan. 2017. tab, graf.
Idioma: en.
Resumo: Canine visceral leishmaniasis (CVL) diagnosis is still a challenge in endemic areas with limited diagnostic resources. This study proposes a score with the potential to distinguish positive CVL cases from negative ones. We studied 265 dogs that tested positive for CVL on ELISA and parasitological tests. A score ranging between 0 and 19 was recorded on the basis of clinical signs. Dogs with CVL had an overall higher positivity of the majority of clinical signs than did dogs without CVL or with ehrlichiosis. Clinical signs such as enlarged lymph nodes (83.93%), muzzle/ear lesions (55.36%), nutritional status (51.79%), bristle condition (57.14%), pale mucosal colour (48.21%), onychogryphosis (58.93%), skin lesion (39.28%), bleeding (12.50%), muzzle depigmentation (41.07%), alopecia (39.29%), blepharitis (21.43%), and keratoconjunctivitis (42.86%) were more frequent in dogs with CVL than in dogs with ehrlichiosis or without CVL. Moreover, the clinical score increased according to the positivity of all diagnostic tests (ELISA, p < 0.001; parasite culture, p = 0.0021; and smear, p = 0.0003). Onychogryphosis (long nails) [odds ratio (OR): 3.529; 95% confidence interval (CI): 1.832-6.796; p < 0.001], muzzle depigmentation (OR: 4.651; 95% CI: 2.218-9.750; p < 0.001), and keratoconjunctivitis (OR: 5.400; 95% CI: 2.549-11.441; p < 0.001) were highly associated with CVL. Interestingly, a score cut-off value ≥ 6 had an area under the curve of 0.717 (p < 0.0001), sensitivity of 60.71%, and specificity of 73.64% for CVL diagnosis. The clinical sign-based score for CVL diagnosis suggested herein can help veterinarians reliably identify dogs with CVL in endemic areas with limited diagnostic resources.
Descritores: Leishmania infantum/imunologia
Doenças do Cão/diagnóstico
Doenças do Cão/epidemiologia
Leishmaniose Visceral/diagnóstico
Leishmaniose Visceral/veterinária
Leishmaniose Visceral/epidemiologia
Antígenos de Protozoários/sangue
-Brasil/epidemiologia
Ensaio de Imunoadsorção Enzimática/veterinária
Sensibilidade e Especificidade
Anticorpos
Limites: Animais
Masculino
Feminino
Cães
Responsável: BR1.1 - BIREME


  5 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-974431
Autor: Santos, Mariana Lopes dos; Quintilio, Wagner; Manieri, Tania Maria; Tsuruta, Lilian Rumi; Moro, Ana Maria.
Título: Advances and challenges in therapeutic monoclonal antibodies drug development
Fonte: Braz. J. Pharm. Sci. (Online);54(spe):e01007, 2018. graf, ilus.
Idioma: en.
Resumo: The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved is provided, showing the development of sophisticated mAbs formats that were engineered based on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. Scientific and technological advances represent mAbs successful translation to the clinic
Descritores: Desenvolvimento Tecnológico/classificação
Anticorpos
Anticorpos Monoclonais/análise
-Camundongos Transgênicos/classificação
Imunoterapia/efeitos adversos
Limites: Animais
Camundongos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  6 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-964587
Autor: Castro, Jacqueline Ribeiro de; Souza, Mariana Assunção de; Cardoso Neto, Antônio Bertolino; Moreira, Rafael Quirino; Salaberry, Sandra Renata Sampaio; Guimarães, Ednaldo Carvalho; Lima, Anna Monteiro Correia.
Título: Presence of antibodies against Leptospira spp. in dogs of Uberlandia, MG, Brazil / Presença de anticorpos contra Leptospira spp. em cães no município de Uberlândia, MG, Brasil
Fonte: Biosci. j. (Online);31(4):1183-1188, july/aug. 2015.
Idioma: en.
Resumo: The aim of this study was to investigate the occurrence of antibodies against Leptospira spp. and risk factors related to the epidemiology of leptospirosis in dogs living in the urban area of the municipality of Uberlandia, Minas Gerais, Brazil. Blood serum samples were examined from 268 dogs from the municipality's North, South, East, West and Central sanitary districts. The samples were collected during an animal vaccination campaign against rabies in August 2008. The occurrence of antibodies against specific leptospiral serovars was determined by the microscopic agglutination test (MAT). Multivariable logistic regression was used to evaluate the association between sex, age, previous vaccination, habitation, presence of rats, and history of human and/or animal leptospirosis on the occurrence of infection. The occurrence of canine leptospirosis was 28.36% (76/268), the most prevalent serovars were: Autumnalis (34.21%), Tarassovi (23.58%), Canicola (17.11%) and Grippotyphosa (14.47%). No risk factors were found to be statistically significant (p> 0,05 for all examined variables). The fact that close to 30% of dogs showed evidence of past infection with Leptospira points to the need for the adoption of preventive measures, as the disease may represent a public health risk.

O objetivo deste estudo foi investigar a ocorrência de anticorpos contra Leptospira spp. e os fatores de risco relacionados à epidemiologia da leptospirose em cães que vivem na área urbana do município de Uberlândia, Minas Gerais, Brasil. Amostras de soro foram examinados a partir de 268 cães dos distritos sanitários Norte, Sul, Leste, Oeste e Central. As amostras foram colhidas durante a campanha de vacinação contra a raiva animal em agosto de 2008. A ocorrência de anticorpos contra sorovares específicos foi determinada pelo teste de Soroaglutinação Microscópica (SAM). Foi utilizada a regressão logística multivariada para avaliar a associação entre sexo, idade, a vacinação, habitação, presença de ratos e história de humanos e/ou leptospirose animal na ocorrência da infecção. A ocorrência da leptospirose canina foi de 28,36% (76/268), os sorovares mais prevalentes foram: Autumnalis (34,21%), Tarassovi (23,58%), Canicola (17,11%) e Grippotyphosa (14,47%). Quanto aos fatores de risco analisados, não foi encontrada diferença estatística significativa (p> 0,05 para todas as variáveis analisadas). O fato de 30% dos cães terem apresentado evidência de infecção causada por Leptospira aponta para a necessidade da adoção de medidas preventivas, pois a doença pode representar um risco para a saúde pública.
Descritores: Modelos Logísticos
Cães
Leptospira
Leptospira interrogans
Anticorpos
Responsável: BR396.1 - Biblioteca Central


  7 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-960435
Autor: Fernández Águila, Julio D; García Vega, Yanelda de los Ángeles; Hernández Casaña, Patricia; Hernández Cruz, Calixto; Medina Rodríguez, Bárbaro Andrés; Viada González, Carmen Elena.
Título: Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior® / Safety and response to treatment of compassionate use of an anti-CD20 monoclonal antibody CIMABior®
Fonte: Rev. cuba. hematol. inmunol. hemoter;33(4):35-49, oct.-dic. 2017. tab.
Idioma: es.
Resumo: Introducción: el uso de anticuerpos monoclonales transformó el tratamiento de los linfomas no hodgkinianos. El Centro de Inmunología Molecular generó un anticuerpo anti-CD20 (CIMABior®) biosimilar del rituximab, que se ha caracterizado desde el punto de vista biológico, pero la seguridad y eficacia aún están en estudio. Objetivo: evaluar la seguridad y la respuesta al tratamiento con CIMABior ®, en pacientes con síndromes linfoproliferativos de células B tratados con intención compasiva. Métodos: estudio multicéntrico, exploratorio, con dos grupos de tratamiento (monoterapia o combinado con quimioterapia) no controlado, ni aleatorizado. Se incluyeron adultos con linfomas no hodgkinianos y leucemia linfocítica crónica, no elegibles para el ensayo clínico en ejecución con este producto. Se determinó la frecuencia de eventos adversos y se caracterizaron. La respuesta al tratamiento se definió como: remisión completa, remisión parcial, enfermedad estable o en progresión. Se calculó la tasa de respuesta objetiva (remisión completa más remisión parcial) con el intervalo de confianza al 95 por ciento, se evaluó la relación de algunas variables con la respuesta y se estimó la razón de Odss. Como medida de balance beneficio-riesgo se estimó el factor de Bayes. Resultados: los eventos adversos más frecuentes fueron: temblor (12,8 por ciento) y fiebre (10,3 por ciento). Los relacionados con el producto (43,4 por ciento) fueron leves o moderados y evolucionaron hacia la recuperación. No se informó muerte asociada directamente al tratamiento. Se constató respuesta objetiva global de 71,2 por ciento (59,6 por ciento de remisiones completas y 11,5 por ciento, parciales). La respuesta objetiva en el grupo de monoterapia fue de 66,7 por ciento y de 73,0 por ciento en el grupo de CIMABior® más quimioterapia, con remisiones completas de 46,7 por ciento y 64,9 por ciento, respectivamente. Conclusiones: el AcM CIMABior® es seguro, bien tolerado y se demostraron evidencias de efecto. El tratamiento aportó un beneficio clínico superior al riesgo de desarrollar algún evento adverso grave(AU)

Introduction : The use of monoclonal antibodies transformed the treatment of non-Hodgkin lymphomas. The Center of Molecular Immunology created an anti-CD20 monoclonal antibody (CIMABior®), biosimilar of rituximab, which has been characterized from a biological point of view, but the safety and effectiveness are still being studied. Objective: Evaluate the safety and response to treatment, in patients with B-cell malignancies with compassionate use of CIMABior®. Methods : A multicenter, exploratory, non-controlled, non-randomized study was conducted with two variants of treatments (monotherapy or combined with chemotherapy). Adults with non-Hodgkin lymphomas and chronic lymphocytic leukemia not eligible for clinical trial with this product were included. Frequency of adverse events was calculated and those were characterized. The response to treatment was defined as: complete response, partial response, stable disease or progressive disease. Overall response rate (complete plus partial remission) was calculated with 95 percent confidence interval. The relation of some variables with response was estimated per Odss ratio. As a measure of the benefit-risk balance, the Bayes factor was estimated. Results : The more frequent adverse events were: tremors (12.8 percent) and fever (10.3 percent). Those related to the product (43.4 percent) were minor and evolved to recovery. There were no deaths in reference to the treatment. An overall response of 71.2 percent was confirmed (59.6 percent complete remissions and 11.5 percent partial remission). The monotherapy group objective response was 66.7 percent and 73.0 percent in the CIMABior® plus chemotherapy group, with complete remissions of 46.7 percent and 64.9 percent respectively. Conclusions: The monoclonal antibodies CIMABor® is safe, well tolerated and evidences of its effectiveness was demonstrated. The treatment provided a superior clinical benefit to the risk of developing a severe adverse event(AU)
Descritores: Linfoma não Hodgkin/terapia
Leucemia de Células B/terapia
-Resultado do Tratamento
Cuba
Ensaios de Uso Compassivo/ética
Citometria de Fluxo/métodos
Antineoplásicos Imunológicos/uso terapêutico
Anticorpos/uso terapêutico
Limites: Seres Humanos
Masculino
Feminino
Responsável: CU1.1 - Biblioteca Médica Nacional


  8 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-985511
Autor: Macchia de Sánchez, Carla Lorena; Sánchez-Flórez, Javier Augusto.
Título: Prevalence of thyroid autoimmunity in a population of pregnant women in Santa Marta, Magdalena (Colombia) / Prevalencia de autoinmunidad tiroidea en una población de gestantes de Santa Marta, Magdalena (Colombia)
Fonte: Rev. colomb. obstet. ginecol;69(4):260-269, Oct.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: To describe the prevalence of thyroid autoimmunity in a hospital-based population of pregnant women, and to explore its frequency in euthyroid and hypothyroid women, as well as the association between autoimmunity and the presence of obstetric complications. Materials and methods: Descriptive cross-sectional study. Accesible population: pregnant women seen at Centros Hospitalarios del Caribe (CEHOCA) in the city of Santa Marta, Magdalena (Colombia), between August 1 and October 31, 2017. Convenience sampling. Sample size: 120 subjects. Thyroid stimulating hormone (TSH), free thyroxine (T4), free triiodothyronine (T3), thyroglobulin (TG) and thyroid peroxidase (TPO) antibodies were determined. Descriptive statistics were used. Prevalence was calculated as the number of women with positive TG or TPO antibodies/number of women surveyed. Categorization by type of positive antibody and thyroid function (normal or hypothyroidism) was also done. Results: In women with uncomplicated pregnancies, the frequency of thyroid autoimmunity was 14.29%. Five patients (4.5%) had positive TPO antibodies, 14 patients (12.61%) had positive TG antibodies, while 3 of the women were positive for the two types of antibodies. Antithyroglobulin antibodies were the most frequent. Autoimmunity was found in 13.5% of euthyroid women, and in 18.2% of the women with subclinical hypothyroidism. No association was found between the presence of antibodies and miscarriage, pregnancy-associated hypertension or preterm delivery. Conclusions: The presence of antithyroid antibodies was found in 1 out of every 7 pregnant women as a sign of autoimmunity. Further observations are required in order to determine frequencies and normality ranges in the local population, as well as the clinical significance of this thyroid autoimmunity.

RESUMEN Objetivo: describir la prevalencia de autoinmunidad tiroidea en una población de gestantes de base hospitalaria, y hacer una exploración a la frecuencia en pacientes eutiroideas o hipotiroideas, y de la asociación entre autoinmunidad y la presencia de complicaciones obstétricas. Materiales y métodos: estudio de corte transversal, descriptivo. Población accesible: gestantes atendidas en Centros Hospitalarios del Caribe (CEHOCA), de la ciudad de Santa Marta, Magdalena (Colombia), entre el 1 de agosto y el 31 de octubre de 2017. Muestreo por conveniencia. Tamaño muestral: 120 sujetos. Se determinó hormona tiroestimulante (TSH), T4 libre, T3 libre, anticuerpos antitiroglobulina (ATG) y antiperoxidasa (ATPO). Se utilizó estadística descriptiva. La prevalencia se calculó como número de mujeres con anticuerpos ATG o ATPO positivos/número de mujeres encuestadas, además se categorizó por tipo de anticuerpo positivo y función tiroidea (normal o hipotiroidismo). Resultados: en las gestantes con embarazo sin mención de complicación la frecuencia de autoinmunidad tiroidea fue del 14,29 %. Cinco pacientes (4,5 %) presentaron anticuerpos ATPO positivos, 14 pacientes (12,61 %) anticuerpos ATG positivos, en tanto que 3 embarazadas mostraron positividad para ambos tipos de anticuerpos. Los anticuerpos antitiroglobulina fueron los más frecuentes. Se halló autoinmunidad en el 13,5 % de las gestantes eutiroideas, y en el 18,2 % de las pacientes con hipotiroidismo subclínico. No se encontró asociación entre la presencia de anticuerpos y la presencia de aborto, hipertensión asociada al embarazo o parto pretérmino. Conclusiones: una de cada 7 gestantes mostró presencia de anticuerpos antitiroideos como signo de autoinmunidad. Son necesarias más observaciones a fin de poder establecer frecuencias y rangos de normalidad en la población local y el significado clínico de esta autoinmunidad tiroidea.
Descritores: Gestantes
-Glândula Tireoide
Tiroxina
Tri-Iodotironina
Tireotropina
Colômbia
Anticorpos
Limites: Seres Humanos
Responsável: CO76


  9 / 997 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1009886
Autor: Barbieri, Elena S; Rodríguez, Daniela V; Marin, Raúl E; Setti, Walter; Romero, Sandra; Barrandeguy, María; Parreño, Viviana.
Título: Relevamiento serológico de anticuerpos contra enfermedades virales de interés sanitario en llamas (Lama glama) de la provincia de Jujuy, Argentina / Serological survey of antibodies aainst vital diseases of public health interest in llamas (Lama glama) from Jujuy rpovince, Argentina
Fonte: Rev. argent. microbiol;46(1):53-57, mar. 2014.
Idioma: es.
Resumo: Las poblaciones de llamas de Argentina se concentran principalmente en la provincia de Jujuy; su explotación representa un importante recurso económico de las comunidades altoandinas. El objetivo de este trabajo fue evaluar la seroprevalencia de anticuerpos contra algunos agentes virales asociados a enfermedades de impacto productivo en rodeos de llamas de Jujuy. Se analizaron 349 sueros de llamas adultas de 6 departamentos de la puna jujeña ubicados por encima de los 3300 msnm. Se obtuvo una prevalencia del 100 % para rotavirus grupo A y del 70 % para el virus parainfluenza-3 bovino, mientras que no se detectaron reactores para herpesvirus bovino 1, virus de la diarrea viral bovina, influenza A humana (H1N1) e influenza equina (H3N8). Los resultados obtenidos confirman la amplia distribución de rotavirus y virus parainfluenza y la baja susceptibilidad a herpesvirus y pestivirus en las tropas de llamas de la puna jujeña

Llama population from Argentina is mainly concentrated in the Andean Puna, Jujuy. Llamas represent an important economic resource for the Andean communities. The aim of this study was to investigate the prevalence of antibodies against viral antigens associated to viral diseases of economic impact (neonatal diarrhea, reproductive and respiratory syndromes). A total of 349 serum samples from adult llamas were analyzed. The obtained antibody prevalence was 100 % for Rotavirus A and 70 % for Bovine parainfluenza virus 3. In contrast, no reactors were detected to Bovine herpesvirus 1, Bovine viral diarrhea virus 1, Human influenza A virus (H1N1) and Equine influenza virus (H3N8). These results confirm the wide circulation of rotavirus and parainfluenza virus in Argentinean llamas and suggest that susceptibility to infection with bovine herpesvirus, pestivirus and influenza A viruses is low. This serologic survey provides novel information regarding the epidemiology of viral diseases affecting llamas from the Argentinean Andean Puna
Descritores: Argentina/epidemiologia
Camelídeos Americanos/imunologia
Anticorpos/análise
-Infecções por Rotavirus/epidemiologia
Estudos Soroepidemiológicos
Infecções por Paramyxoviridae/epidemiologia
Rotavirus/isolamento & purificação
Herpesvirus Bovino 1/isolamento & purificação
Vírus da Parainfluenza 3 Bovina/isolamento & purificação
Vírus da Influenza A Subtipo H1N1/isolamento & purificação
Vírus da Influenza A Subtipo H3N8/isolamento & purificação
Limites: Animais
Tipo de Publ: Estudos de Avaliação
57664
Responsável: AR635.1 - FCVyS - Servicio de Información y Documentación


  10 / 997 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-681968
Autor: Silva, Silvia Fernandes Ribeiro da; Ferreira, Glaucia Maria; Silva, Sonia Leite da; Alves, T ania Maria de Oliveira; Ribeiro, Ilana Farias; Ribeiro, Thyciana Rodrigues; Cavalcante, Maria do Carmo Serpa.
Título: Red blood cell and leukocyte alloimmunization in patients awaiting kidney transplantation
Fonte: Rev. bras. hematol. hemoter;35(3):185-188, jun. 2013. tab.
Idioma: en.
Resumo: Objective: To determine the rates of red blood cell and leukocyte alloimmunization in patients with chronic kidney disease awaiting kidney transplantation. Methods: In this cross-sectional and prospective study, the serum of 393 chronic kidney disease patients on a transplant waiting list in Ceará, Northeastern Brazil were tested for red cell and leukocyte antibodies. In addition, demographic, clinical and laboratory data were collected. Results: The average age in the sample of 393 patients was 34.1 ± 14 years. Slightly more than half (208; 52.9%) were male. The average numbers of transfusions and gestations were 3.1 ± 3.3 and 1.6 ± 6, respectively. One third (33.6%) were alloimmunized: 78% with leukocyte antibodies, 9.1% with red cell antibodies and 12.9% with both. Red cell antibodies were detected in 29 cases (7.4%), 17 of whom were women, who had received more transfusions than the males (p-value < 0.0001). The most frequently detected red cell antibodies belonged to the Rh (24.1%) and Kell (13.8%) blood group systems. Leukocyte antibodies were detected in 30.5% of cases, 83 of whom were women, who had received more transfusions than the males (p-value < 0.0001) and were more reactive to panel reactive antibodies (p-value < 0.0001). The mean alloreactivity to panel reactive antibodies was 47.7 ± 31.2%. Conclusion: Chronic kidney disease patients on the transplant waiting list in Ceará, Brazil, display high ...
Descritores: Transfusão de Sangue
Estudos Transversais
Transplante de Rim
Transfusão de Eritrócitos
Insuficiência Renal
Falência Renal Crônica
Anticorpos
Limites: Seres Humanos
Masculino
Feminino
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM



página 1 de 100 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde